Author(s): Powe DG, Entschladen F
Abstract Share this page
Abstract Three recent population studies have translated laboratory investigations into a clinical setting and concur in presenting evidence that suggest a dramatic new role for β-blockers in reducing metastases, tumor recurrence and specific mortality in breast cancer. Should we be skeptical about these controversial findings?
This article was published in Nat Rev Clin Oncol
and referenced in Journal of Cancer Science & Therapy